An integrative bioinformatics approach in microRNA data analytics of alzheimer’s disease
Alzheimer’s Disease (AD) is the most common type of dementia clinically recognised by cognitive function impairment. Lately, the blood-based biomarkers relating to AD are intensively investigated due to the minimum invasiveness and relatively low cost in the collection of blood samples compared t...
Saved in:
Main Author: | |
---|---|
Format: | Conference or Workshop Item |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/38236/1/AJCC2023_paper_6608.pdf http://eprints.um.edu.my/38236/ https://www.ajcc-conf.net/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Alzheimer’s Disease (AD) is the most common type of dementia clinically recognised by
cognitive function impairment. Lately, the blood-based biomarkers relating to AD are
intensively investigated due to the minimum invasiveness and relatively low cost in the
collection of blood samples compared to the cerebrospinal fluid in the brain. With regard
to that, the study of the deregulation of microRNA (miRNA) levels in the blood of AD
patients is on the rise too. In this study, data analysis was performed on the miRNA
expression profiling dataset using an integrative bioinformatics approach. kNN
imputation and quantile normalization were carried out as the data pre-processing step to
remove outliers and reduce bias in the dataset. Differential expression analysis was
performed to identify 10 significant dysregulated miRNAs using a cut-off at adjusted-pvalue
<0.05 and an absolute fold change of 1.6. Subsequently, 16 pathways were
determined to be involved by the selected 10 miRNA signatures, and 7 genes were
predicted as the common target genes, which are Cdc42, VEGFA, NTRK3, ESR1,
SH3GL2, COX-2 and E2F1. The roles of these target genes in AD were proven by
literature studies. Expansion of the current work on a bigger scale of data analysis is
needed to further validate and understand the mechanism of miRNAs in AD development. |
---|